Biotechnology · Winston-Salem, North Carolina, United States
$1.76
-1.12% (-$0.02)2026-07-10
Smart-Money SignalNeutral · 50/100— Insider open-market flow is flat over 90 days
Revenue$226.0K
Net Income-$20.0M
Price Performance
Historical data including institutional events
Company Profile
B
Bruce Culleton
CEO & Executive Director
ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States.
The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes.
It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-008 which are both in Phase III clinical trials; REGEN-002, REGEN-003, and REGEN-007 which are in Phase II clinical trials; and REGEN-004 which is Phase I clinical trial.
The company was founded in 2015 and is headquartered in Winston-Salem, North Carolina.
